JANONE INC (JAN) Stock Fundamental Analysis

Name: JANONE INC (JAN) Stock
Brand: JANONE INC
Rating: 0.5 (3 reviews)

USA - Nasdaq - NASDAQ:JAN - US47089W1045 - Common Stock

2.23 USD

+0.09 (+4.21%)

Last: 7/12/2024, 8:00:02 PM

Fundamental Rating

We assign a fundamental rating of 0 out of 10 to JAN. JAN was compared to 191 industry peers in the Pharmaceuticals industry. JAN may be in some trouble as it scores bad on both profitability and health. JAN has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

JAN had negative earnings in the past year.
JAN had a negative operating cash flow in the past year.
In the past 5 years JAN reported 4 times negative net income.
In the past 5 years JAN reported 4 times negative operating cash flow.

1.2 Ratios

JAN's Return On Assets of -107.89% is on the low side compared to the rest of the industry. JAN is outperformed by 83.08% of its industry peers.
JAN has a worse Return On Equity (-262.72%) than 76.92% of its industry peers.

		Industry Rank	Sector Rank
ROA	-107.89%
ROE	-262.72%
ROIC	N/A

ROA(3y)-43.38%

ROA(5y)-41.28%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

JAN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

JAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
JAN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, JAN has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.96, we must say that JAN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of JAN (-3.96) is worse than 60.00% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that JAN is not too dependend on debt financing.
JAN's Debt to Equity ratio of 0.14 is in line compared to the rest of the industry. JAN outperforms 46.15% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.14
Debt/FCF	N/A
Altman-Z	-3.96

ROIC/WACCN/A

WACC9.51%

2.3 Liquidity

JAN has a Current Ratio of 0.15. This is a bad value and indicates that JAN is not financially healthy enough and could expect problems in meeting its short term obligations.
JAN has a Current ratio of 0.15. This is amonst the worse of the industry: JAN underperforms 98.46% of its industry peers.
JAN has a Quick Ratio of 0.15. This is a bad value and indicates that JAN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.15, JAN is not doing good in the industry: 97.95% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.15
Quick Ratio	0.15

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for JAN have decreased strongly by -163.18% in the last year.
The Revenue for JAN has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)-163.18%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-110.79%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.